Arbutus Biopharma Corp is a US-based pharmaceutical company with a risk rating score of 25.5, placing it at a medium risk level. Specializing in treatments for Hepatitis B, Arbutus Biopharma Corp is dedicated to environmental sustainability and governance practices. With a focus on developing a diverse portfolio of drug candidates, the company is also known for its involvement in licensing Lipid nanoparticle technology.